Trial Profile
An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE-17)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RESONATE-17; RESONATE-17p
- Sponsors Pharmacyclics
- 14 Jun 2023 Results assessing frequency and time to detection of BTK and PLCG2 mutations in peripheral blood samples across 5 clinical trials (NCT01500733, NCT01578707, NCT01722487, NCT01744691 and NCT02264574) published in the Clinical Cancer Research
- 07 Oct 2020 Development and validation of a four-factor prognostic model in Patients With Chronic Lymphocytic Leukemia treated with Ibrutinib; results published in the Journal of Clinical Oncology
- 04 Dec 2018 Results of validation of prognostic model using pooled data of pooled analysis of four phase II and III studies (NCT01105247; NCT01578707; NCT01722487; NCT01744691), presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.